Φορτώνει......
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Novel agents such as the Bcl-2 inhibitor venetoclax (ABT-199) are changing treatment paradigms for chronic lymphocytic leukemia (CLL) but important problems remain. Although some patients exhibit deep and durable responses to venetoclax as a single agent, other patients harbor subpopulations of resi...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Hematology
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5000578/ https://ncbi.nlm.nih.gov/pubmed/27297795 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-687814 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|